Abstract:In rats, treatment with spironolactone or pregnenolone-16α-carbonitrile (PCN) accelerates bile flow and enhances hepatic microsomal bilirubin–UDP glucuronyltransferase activity (EC 2.4.1.17) and the biliary transport maximum (Tm) of bilirubin. The distribution of ethylanthranilate azo-pigments in fractions separated by thin-layer chromatography also indicates increased glucuronidation of bilirubin. These findings explain the mechanism of enhanced serum bilirubin disappearance in rats treated with the steroids.
“…In addition, PCN induces Z protein and, as an associated change, it increases the capacity of the liver to take up and store bilirubin and BSP. These findings are in total agreement with earlier investigations (17,18) in which it was shown that PCN enhances serum bilirubin clearance in rats.…”
Section: Discussionsupporting
confidence: 94%
“…Like phénobarbital, certain microsomal enzyme inducers -for instance, pregnenolone16a-carbonitrile (PCN) and spironolactonehave been shown to accelerate the clearance of bilirubin from serum (17), stimulate bile flow and increase hepatic microsomal bilirubin-UDP glucuronyltransferase activity as well as die biliary Tm of bilirubin (2,18).…”
mentioning
confidence: 99%
“…The induction by PCN of Y protein -the major organic anion binding protein in the liver (6) -suggests a possible effect of this cyanosteroid on tissue bilirubin distribution, an effect wliich may be independent of its direct influence on the microsomal enzyme system. In view of its stimulation of bilirubin glucuronyltransferase and lowering of plasma bilirubin levels in ex perimental hyperbilirubinemia (18), PCN -like phénobarbital -appears to fulfill most of the requirements as an aid in the prevention and/or treatment of kemicterus.…”
Pregnenolone-16α-carbonitrile (PCN), administered twice daily p.o. for 3 days at a dose level of 20 μmol/100 g body weight, significantly enhances the in vivo binding of 14C-bilirubin and sulfobromophthalein (BSP) to hepatic Y and Z proteins in female Charles River CD® rats. 14C-bilirubin-binding to Y protein showed a 61% increase, while binding of the same moiety to the Z protein fraction was augmented by 59%. BSP-binding in vivo demonstrated rises of 114 and 71% in relation to Y and Z proteins, respectively. These data correlate well with previous investigations in which PCN was found to have a beneficial influence on experimentally induced hyperbilirubinemias and, furthermore, there is an indication that phenobarbital, another potent microsomal enzyme inducer, acts via a similar mechanism.
“…In addition, PCN induces Z protein and, as an associated change, it increases the capacity of the liver to take up and store bilirubin and BSP. These findings are in total agreement with earlier investigations (17,18) in which it was shown that PCN enhances serum bilirubin clearance in rats.…”
Section: Discussionsupporting
confidence: 94%
“…Like phénobarbital, certain microsomal enzyme inducers -for instance, pregnenolone16a-carbonitrile (PCN) and spironolactonehave been shown to accelerate the clearance of bilirubin from serum (17), stimulate bile flow and increase hepatic microsomal bilirubin-UDP glucuronyltransferase activity as well as die biliary Tm of bilirubin (2,18).…”
mentioning
confidence: 99%
“…The induction by PCN of Y protein -the major organic anion binding protein in the liver (6) -suggests a possible effect of this cyanosteroid on tissue bilirubin distribution, an effect wliich may be independent of its direct influence on the microsomal enzyme system. In view of its stimulation of bilirubin glucuronyltransferase and lowering of plasma bilirubin levels in ex perimental hyperbilirubinemia (18), PCN -like phénobarbital -appears to fulfill most of the requirements as an aid in the prevention and/or treatment of kemicterus.…”
Pregnenolone-16α-carbonitrile (PCN), administered twice daily p.o. for 3 days at a dose level of 20 μmol/100 g body weight, significantly enhances the in vivo binding of 14C-bilirubin and sulfobromophthalein (BSP) to hepatic Y and Z proteins in female Charles River CD® rats. 14C-bilirubin-binding to Y protein showed a 61% increase, while binding of the same moiety to the Z protein fraction was augmented by 59%. BSP-binding in vivo demonstrated rises of 114 and 71% in relation to Y and Z proteins, respectively. These data correlate well with previous investigations in which PCN was found to have a beneficial influence on experimentally induced hyperbilirubinemias and, furthermore, there is an indication that phenobarbital, another potent microsomal enzyme inducer, acts via a similar mechanism.
“…Different steroids might be involved or other hormones might be required to allow an effect of estrogens and progestogens to become manifest, thus exerting a permissing effect. It has also been proposed that alterations of drug-metabolizing enzymes during pregnancy is a consequence of a shift of hepatic progesterone metabolism from the hydroxylation pathway, producing inducers of microsomal enzymes such as pregnenolone 16a-carbonitrile, to the reduction pathway, producing inhibitors of microsomal enzymes such as pregnanediol (29). This hypothesis could also explain the present results, since pregnenolone-16a-carbonitrile was found to induce hepatic bilirubin conjugation (29) while pregnanendiol was found to inhibit it (30).…”
Hepatic bilirubin conjugation and excretion were investigated during pregnancy and lactation in the rat. Bilirubin uridine diphosphate-glucuronyltransferase activity was decreased by 30% in pregnant rats, both when expressed per milligram of protein or as specific activity and per unit of liver weight. Liver size increased during pregnancy, and, as a consequence, total hepatic glucuronyltransferase activity was unchanged. The biliary bilirubin output was normal in pregnant rats, and when loaded with bilirubin, the maximal output in bile for the whole liver was also normal. In lactating rats, specific glucuronyltransferase activity returned to control values, but the activity per unit of liver weight was still lower, due to the decreased hepatic protein concentration. The liver remained enlarged during lactation, and total hepatic glucuronyltransferase activity was increased, together with the maximal output of bilirubin in bile. Two weeks after delivery, hepatic bilirubin conjugation and excretion in nonlactating mothers were comparable to those of virgin females. Parallel modifications of bilirubin glucuronyltransferase assayed in vitro and of maximal biliary output of the pigment in vivo were observed in all animals studied. The output of bilirubin diconjugates in bile was decreased during pregnancy but no changes of the proportion of the mono-to diconjugates in bile were observed 2 weeks after delivery both in lactating and in nonlactating rats. The modifications observed during pregnancy could not be reproduced by treatment with beta-estradiol and progesterone. This suggests that different hormones or modifications of steroid metabolism are probably involved in the alterations of hepatic bilirubin metabolism in pregnant and lactating rats.
“…In the rat, PCN increases bile flow as well as the glucuronidation of bilirubin and clearance of sulphobromophthelein (BSP) (Zsigmond & Solymoss, 1972;Solymoss & Zsigmond, 1973). It also counters toxic effects of many substances in the rat (Selye, 1971).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.